

**Amendments to the Claims**

Please cancel Claims 28-32.

Please amend Claims 3, 18, 20, 24 and 33-35.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

Claims 1.-2. (Canceled).

3. (Currently Amended) A method of treating ~~TNF $\alpha$ -mediated inflammatory and immune disease~~ psoriasis in a human in need thereof comprising administering to the human an effective tumor necrosis factor alpha (TNF $\alpha$ )-inhibiting amount of an anti-TNF $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNF $\alpha$  antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF $\alpha$  and (ii) binds to a neutralizing epitope of human TNF $\alpha$  ~~in vivo~~ with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>), as determined by Scatchard analysis.

Claims 4.-13. (Canceled).

14. (Previously Presented) The method of Claim 3 wherein the anti-TNF $\alpha$  antibody or antigen-binding fragment is administered to the human by means of parenteral administration.
15. (Previously Presented) The method of Claim 3 wherein the anti-TNF $\alpha$  antibody or antigen-binding fragment is administered to the human by means of intravenous administration, or subcutaneous administration.
16. (Canceled).

17. (Previously Presented) The method of Claim 3 wherein said TNF $\alpha$ -inhibiting amount of said anti-TNF $\alpha$  antibody or antigen-binding fragment comprises a single or divided dose of about 0.1 - 50 mg/kg.
18. (Currently Amended) The method of Claim 17 wherein the single or divided dose is one selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose 0.5, 0.9, 1, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mg/kg per day on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
19. (Canceled).
20. (Currently Amended) A method of treating ~~TNF $\alpha$ -mediated inflammatory and immune disease~~ psoriasis in a human in need thereof comprising administering to the human an effective tumor necrosis factor alpha (TNF $\alpha$ )-inhibiting amount of an anti-TNF $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human IgG1 constant region, wherein said anti-TNF $\alpha$  antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF $\alpha$  and (ii) binds to a neutralizing epitope of human TNF $\alpha$  ~~in vivo~~ with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>), as determined by Scatchard analysis.
21. (Previously Presented) The method of Claim 3, wherein said antibody or antigen-binding fragment is of immunoglobulin class IgG1, IgG2, IgG3, IgG4 or IgM.
22. (Previously Presented) The method of Claim 3, wherein said antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub> and Fv.
23. (Previously Presented) The method of Claim 3, wherein the antibody or antigen-binding fragment thereof comprises at least one human framework region.

24. (Currently Amended) The method of Claim 3, wherein said ~~TNF $\alpha$ -mediated inflammatory and immune disease~~ psoriasis results in tissue injury.
25. (Previously Presented) The method of Claim 3, wherein the antibody or antigen-binding fragment comprises a human constant region and a human variable region.
26. (Previously Presented) The method of Claim 3, wherein the antibody or antigen-binding fragment comprises at least one human light chain and at least one human heavy chain.
27. (Previously Presented) The method of Claim 3, wherein said analysis comprises labelling the anti-TNF $\alpha$  antibody or antigen-binding fragment thereof and measuring direct binding of <sup>125</sup>I labelled anti-TNF $\alpha$  antibody or antigen-binding fragment thereof to immobilized rhTNF $\alpha$ , and wherein said antibodies are labelled to a specific activity of about 9.7  $\mu$ Ci/ $\mu$ g by the iodogen method.

Claims 28.-32. (Canceled).

33. (Currently Amended) A method of treating ~~TNF $\alpha$ -mediated inflammatory and immune processes~~ psoriasis in a human in need thereof comprising administering to the human an effective tumor necrosis factor alpha (TNF $\alpha$ )-inhibiting amount of an anti-TNF $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNF $\alpha$  antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF $\alpha$  and (ii) binds to a neutralizing epitope of human TNF $\alpha$  ~~in-vivo~~ with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>), as determined by Scatchard analysis.
34. (Currently Amended) The method of Claim 33, wherein said ~~TNF $\alpha$ -mediated inflammatory and immune processes are~~ psoriasis is a chronic inflammatory and immune processes process.

35. (Currently Amended) The method of Claim 33, wherein said ~~TNF $\alpha$ -mediated~~  
~~inflammatory and immune processes are~~ psoriasis is an acute inflammatory and immune  
~~processes~~ process.